A retrospective multicenter study assessing the efficacy and safety of Nivolumab plus Ipilimumab (NPI) versus Nivolumab alone (NIV) in patients with treatment-naive programmed death-ligand 1 (PD-L1) positive metastatic Soft Tissue Sarcomas
Latest Information Update: 26 May 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Leiomyosarcoma; Lipoma; Liposarcoma; Myxoid liposarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 26 May 2021 New trial record